SETD2 and cancer: Other than the seven previously reported cancer types presenting significant mutations in either IDH1 or SETD2 in the high-methylation group, we found four additional cancer types with small groups of patients whose mutational status significantly correlated with the increased CIMP score (Figure 3E, Supplemental Table 6).